文献速递产科母胎医学

妊娠期哮喘

Asthma in Pregnancy.
PubMed 文献 · Obstet Gynecol · 2025-06-05

哮喘影响高达10%的妊娠,对母婴均构成风险。孕期哮喘控制不佳与先兆子痫、早产、剖宫产、低出生体重及小于胎龄儿等不良结局相关。吸入性糖皮质激素孕期安全,应作为所有哮喘孕妇的治疗基石,并应积极劝阻孕期停用或降阶梯治疗。

要点

  • 哮喘影响高达10%的妊娠,与先兆子痫、早产、剖宫产、低出生体重和小于胎龄儿风险增加相关。
  • 吸入性糖皮质激素孕期安全,可减少症状、预防急性发作并减轻部分不良妊娠结局。
  • 临床医生应积极劝阻孕期停用或降阶梯哮喘治疗,并对急性发作及时使用全身糖皮质激素和支气管扩张剂。

核心结论

  • 吸入性糖皮质激素应作为所有哮喘孕妇治疗方案的主要组成部分, preferably 使用吸入性糖皮质激素与速效支气管扩张剂的组合吸入器用于按需使用,对症状更持续或并发症风险因素者用于每日维持治疗。
  • 临床医生应积极劝阻孕期停用或降阶梯哮喘治疗,并教育女性这些药物对自身和后代的安全性和重要性。
  • 孕期哮喘急性发作带来额外风险,必须及时识别并使用全身糖皮质激素和支气管扩张剂治疗。

研究设计与样本

  • 本文为临床专家系列综述,提供妊娠期哮喘的概述,重点讨论其潜在不良健康影响及妊娠期哮喘评估和治疗的核心原则。

主要发现

  • 哮喘影响高达10%的妊娠,对母婴均构成风险。
  • 与哮喘相关的不良母体结局包括先兆子痫、早产和剖宫产风险增加。
  • 母体哮喘还增加低出生体重和小于胎龄儿出生体重以及儿童呼吸系统疾病的风险,包括新生儿呼吸窘迫和早发型哮喘。
  • 证据表明,妊娠期慢性哮喘和急性哮喘急性发作均治疗不足。
  • 非妊娠个体的近期里程碑临床试验显示,即使对于轻度疾病患者,使用按需吸入性糖皮质激素联合长效支气管扩张剂作为补救治疗可显著减少急性发作。

关键数值与推荐

  • 哮喘影响高达10%的妊娠。
  • 吸入性糖皮质激素被认为在妊娠期安全,并有效减少症状、预防急性发作并减轻部分不良妊娠结局。
  • 吸入性糖皮质激素应作为所有哮喘孕妇治疗方案的主要组成部分, preferably 使用吸入性糖皮质激素与速效支气管扩张剂的组合吸入器用于按需使用,对症状更持续或并发症风险因素者用于每日维持治疗。
  • 孕期哮喘急性发作必须及时识别并使用全身糖皮质激素和支气管扩张剂治疗。

临床怎么用

  • 临床医生应积极劝阻孕期停用或降阶梯哮喘治疗,并教育女性这些药物对自身和后代的安全性和重要性。
  • 孕期哮喘急性发作必须及时识别并使用全身糖皮质激素和支气管扩张剂治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Asthma affects up to 10% of pregnancies and confers risk to both mother and child. Adverse maternal outcomes associated with asthma include preeclampsia, preterm labor, and increased risk of cesarean delivery. Maternal asthma also increases risks of low birth weight and small-for-gestational-age birth weight, as well as pediatric respiratory disease, including neonatal respiratory distress and early-onset asthma. Despite these risks, evidence suggests that both chronic asthma and acute asthma exacerbations remain undertreated in pregnancy. Recent landmark clinical trials in nonpregnant individuals have shown that, even for patients with mild disease, using as-needed inhaled corticosteroids combined with long-acting bronchodilators as rescue therapy dramatically reduces exacerbations. Inhaled corticosteroids are considered safe in pregnancy and are effective in reducing symptoms, preventing exacerbations, and mitigating some adverse pregnancy outcomes. Therefore, inhaled corticosteroids should be included as a mainstay in the treatment regimens of all pregnant women with asthma, preferably with an inhaled corticosteroid and rapid-onset bronchodilator combination inhaler for as-needed use and for daily maintenance use in those with more persistent asthma symptoms or risk factors for complications. Clinicians should actively discourage discontinuation or de-escalation of asthma therapies during pregnancy and educate women on the safety and importance of these medications for both themselves and their offspring. Asthma exacerbations during pregnancy confer additional risk, so they must be promptly recognized and treated with systemic corticosteroids and bronchodilators. This Clinical Expert Series article provides an overview of asthma in pregnancy, with a focus on its potential adverse health effects and the core principles of asthma evaluation and treatment in pregnancy.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sigelko AD, Strek ME, Wolfe KS, et al. Asthma in Pregnancy. Obstet Gynecol. 2025. PMID: 40472372. doi:10.1097/AOG.0000000000005948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。